1. Home
  2. MTVA
  3. MTVA News

Latest METAVIA INC (MTVA) News on June 7, 2025

MetaVia Announces Poster Presentation on DA-1241 at the ADA's 85th Scientific Sessions
MTVA

PR Newswire

3 days ago

MetaVia Announces Poster Presentation on DA-1241 at the ADA's 85th Scientific Sessions

MTVA: Additional Positive Topline Results for DA-1726 in Phase 1 MAD Study…
MTVA

Zacks Small Cap Research

16 days ago

MTVA: Additional Positive Topline Results for DA-1726 in Phase 1 MAD Study…

Presenting on Emerging Growth Conference 82 Day 1 on May 21; Register to live stream
MTVA

GlobeNewswire

18 days ago

Presenting on Emerging Growth Conference 82 Day 1 on May 21; Register to live stream

MetaVia Reports First Quarter 2025 Financial Results and Provides Corporate Update
MTVA

PR Newswire

23 days ago

MetaVia Reports First Quarter 2025 Financial Results and Provides Corporate Update

MetaVia Announces $10.0 Million Private Placement Priced At-The-Market under Nasdaq Rules
MTVA

PR Newswire

a month ago

MetaVia Announces $10.0 Million Private Placement Priced At-The-Market under Nasdaq Rules

MetaVia Presents Data on DA-1241, a GPR119 Agonist, Demonstrating Both Hepatoprotective and Glucose-Regulating Effects in Patients with Presumed MASH, at the EASL Congress 2025
MTVA

PR Newswire

a month ago

MetaVia Presents Data on DA-1241, a GPR119 Agonist, Demonstrating Both Hepatoprotective and Glucose-Regulating Effects in Patients with Presumed MASH, at the EASL Congress 2025

MetaVia Announces Late-Breaking Poster Presentation on DA-1241 at the EASL Congress 2025
MTVA

PR Newswire

a month ago

MetaVia Announces Late-Breaking Poster Presentation on DA-1241 at the EASL Congress 2025

MetaVia Reports Additional Positive Top-Line Results From the MAD Part 2 of Its Phase 1 Study of DA-1726, a Novel 3:1 Ratio GLP-1 and Glucagon Dual Receptor Agonist to Treat Obesity, Further Demonstrating Its Best-In-Class Potential
MTVA

PR Newswire

2 months ago

MetaVia Reports Additional Positive Top-Line Results From the MAD Part 2 of Its Phase 1 Study of DA-1726, a Novel 3:1 Ratio GLP-1 and Glucagon Dual Receptor Agonist to Treat Obesity, Further Demonstrating Its Best-In-Class Potential

MTVA: Positive Phase 1 MAD Data for DA-1726; Excellent Tolerability Profile and Mean Day 26 Weight Loss of 4.3%…
MTVA

Zacks Small Cap Research

2 months ago

MTVA: Positive Phase 1 MAD Data for DA-1726; Excellent Tolerability Profile and Mean Day 26 Weight Loss of 4.3%…

MTVA

MT Newswires

2 months ago

MetaVia Reports 'Positive' Results for Obesity Treatment in Part 2 of Phase 1 Trial

MetaVia Announces Positive Top-Line Data From the 4-Week Phase 1 MAD Trial of DA-1726, a Novel 3:1 Ratio GLP-1 Glucagon Dual Receptor Agonist to Treat Obesity, Showing Compelling Weight Loss and Safety Effects With Potential Best-In-Class Glucose Control (GLP-1R), Waist Reduction (GCGR), and Tolerability
MTVA

PR Newswire

2 months ago

MetaVia Announces Positive Top-Line Data From the 4-Week Phase 1 MAD Trial of DA-1726, a Novel 3:1 Ratio GLP-1 Glucagon Dual Receptor Agonist to Treat Obesity, Showing Compelling Weight Loss and Safety Effects With Potential Best-In-Class Glucose Control (GLP-1R), Waist Reduction (GCGR), and Tolerability

MTVA: Phase 1 Part 2 Data for DA-1726 in Obesity Expected Soon…
MTVA

Zacks Small Cap Research

2 months ago

MTVA: Phase 1 Part 2 Data for DA-1726 in Obesity Expected Soon…

MetaVia Reports Year End 2024 Financial Results and Provides Corporate Update
MTVA

PR Newswire

3 months ago

MetaVia Reports Year End 2024 Financial Results and Provides Corporate Update

Zacks Small Cap Research 2024 Initiations and Best Ideas for 2025
MTVA

Zacks Small Cap Research

5 months ago

Zacks Small Cap Research 2024 Initiations and Best Ideas for 2025

MetaVia to Hold Advisory Committee Meeting at the 9th Annual MASH-TAG 2025 Conference
MTVA

PR Newswire

5 months ago

MetaVia to Hold Advisory Committee Meeting at the 9th Annual MASH-TAG 2025 Conference

MTVA: Compelling Data for DA-1241 in Phase 2a MASH Trial…
MTVA

Zacks Small Cap Research

6 months ago

MTVA: Compelling Data for DA-1241 in Phase 2a MASH Trial…

MetaVia to Participate in the 9th Annual MASH-TAG 2025 Conference After Releasing Positive Top-Line Results From Its Phase 2a Clinical Trial of DA-1241 in Patients with Presumed MASH
MTVA

PR Newswire

6 months ago

MetaVia to Participate in the 9th Annual MASH-TAG 2025 Conference After Releasing Positive Top-Line Results From Its Phase 2a Clinical Trial of DA-1241 in Patients with Presumed MASH

MetaVia Announces Positive Top-Line Results From Its Phase 2a Clinical Trial of DA-1241 in Patients with Presumed MASH
MTVA

PR Newswire

6 months ago

MetaVia Announces Positive Top-Line Results From Its Phase 2a Clinical Trial of DA-1241 in Patients with Presumed MASH

Winter 2024 Investor Summit Virtual: Q4 Presentations Now Available for On-Demand Viewing
MTVA

ACCESSWIRE

6 months ago

Winter 2024 Investor Summit Virtual: Q4 Presentations Now Available for On-Demand Viewing

Presenting on the Emerging Growth Conference 77 Day 1 on December 4th Register Now
MTVA

GlobeNewswire

6 months ago

Presenting on the Emerging Growth Conference 77 Day 1 on December 4th Register Now

MTVA: NeuroBo Becomes MetaVia; Topline Results for Phase 2a Trial of DA-1241 in MASH Expected in December 2024…
MTVA

Zacks Small Cap Research

6 months ago

MTVA: NeuroBo Becomes MetaVia; Topline Results for Phase 2a Trial of DA-1241 in MASH Expected in December 2024…

MetaVia to Present at the Emerging Growth Conference in December
MTVA

PR Newswire

6 months ago

MetaVia to Present at the Emerging Growth Conference in December

Share on Social Networks: